Arvinas Q2 revenue falls 71%, net loss widens

Arvinas

06/08/2025 12:17

Overview

Arvinas reported Q2 revenue of $22.4 mln, down from $76.5 mln yr ago

Net loss for Q2 widens to $61.2 mln from $35 mln last year

Co submitted NDA for vepdegestrant, first PROTAC degrader to reach this stage

Outlook

Arvinas plans to continue market preparations for vepdegestrant

Company to present vepdegestrant trial data at ESMO Congress October 2025

Arvinas expects to share ARV-102 trial data in 2H 2025

Company believes cash reserves will fund operations into 2H 2028

Result Drivers

REVENUE DECLINE - Decreased revenue due to completion of Novartis License Agreement and adjustments in Pfizer collaboration

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$22.40 mln
Q2 Net Income
-$61.20 mln
Q2 Operating Expenses
$93.90 mln
Q2 Operating income
-$71.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arvinas Inc is $14.00, about 45.6% above its August 5 closing price of $7.61

Press Release: ID:nGNX4zrN4Z

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)